Activity Overview
This online, on-demand virtual symposium brings together renowned experts in breast cancer. In this educational program, these experts provide guidance on integrating and sequencing HER2- and TROP2-directed antibody-drug conjugate (ADC) therapies to optimize patient selection and improve outcomes across early and advanced breast cancer settings.
This educational activity is an archive of the live symposium held on March 6, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, pathologists, advanced practice providers, nurses, pharmacists, and other healthcare practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial evidence supporting TROP2- and HER2-directed ADCs for appropriate integration into metastatic breast cancer management
- Develop individualized treatment sequences incorporating TROP2- and HER2-directed ADC therapies based on biomarker and patient characteristics
- Implement multidisciplinary protocols to monitor and manage adverse events
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here